Guardant Health Inc. is a precision oncology company that specializes in liquid biopsy tests for cancer detection, monitoring, and treatment. The company’s flagship product, Guardant360, drives revenue through diagnostic testing and strategic collaborations with healthcare providers and pharmaceutical firms. Led by CEO Helmy Eltoukhy, Guardant Health has established a competitive edge in genomic profiling within the molecular diagnostics market. It is now focused on expanding its product portfolio and global reach despite facing regulatory and market challenges.
One customer (Customer B) accounted for 28% of revenue in 2025 (29% in 2024 and 31% in 2023), and revenue attributable to Medicare accounted for more than 10% of total revenue in each of 2025, 2024 and 2023.